These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21570494)

  • 1. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.
    Visentini M; Ludovisi S; Petrarca A; Pulvirenti F; Zaramella M; Monti M; Conti V; Ranieri J; Colantuono S; Fognani E; Piluso A; Tinelli C; Zignego AL; Mondelli MU; Fiorilli M; Casato M
    Autoimmun Rev; 2011 Sep; 10(11):714-9. PubMed ID: 21570494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
    Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
    Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of low-dose rituximab for mixed cryoglobulinemia.
    Visentini M; Granata M; Veneziano ML; Borghese F; Carlesimo M; Pimpinelli F; Fiorilli M; Casato M
    Clin Immunol; 2007 Oct; 125(1):30-3. PubMed ID: 17692572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?
    Ahmed MS; Wong CF
    J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
    Quartuccio L; Soardo G; Romano G; Zaja F; Scott CA; De Marchi G; Fabris M; Ferraccioli G; De Vita S
    Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy.
    Mazzaro C; Franzin F; Tulissi P; Pussini E; Crovatto M; Carniello GS; Efremov DG; Burrone O; Santini G; Pozzato G
    Cancer; 1996 Jun; 77(12):2604-13. PubMed ID: 8640712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma.
    Saadoun D; Pineton de Chambrun M; Hermine O; Karras A; Choquet S; Jego P; Decaux O; Cacoub P
    Arthritis Care Res (Hoboken); 2013 Apr; 65(4):643-7. PubMed ID: 22972527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical spectrum, treatment, and outcome of patients with type II mixed cryoglobulinemia without evidence of hepatitis C infection.
    Foessel L; Besancenot JF; Blaison G; Magy-Bertrand N; Jaussaud R; Etienne Y; Maurier F; Audia S; Martin T
    J Rheumatol; 2011 Apr; 38(4):716-22. PubMed ID: 21239761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin's lymphoma.
    Martyak LA; Yeganeh M; Saab S
    Clin Gastroenterol Hepatol; 2009 Aug; 7(8):900-5. PubMed ID: 19362606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia.
    Korte MR; van Heerde MJ; de Man RA; Betjes MH
    Neth J Med; 2008 Jan; 66(1):27-30. PubMed ID: 18219065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
    Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
    Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens.
    Marignani M; Mangone M; Cox MC; Angeletti S; Veggia B; Ferrari A; di Fonzo M; Begini P; Gigante E; Laverde G; Aloe-Spiriti A; Monarca B; Delle Fave G
    Dig Liver Dis; 2011 Feb; 43(2):139-42. PubMed ID: 20554488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients.
    Cohen P; Nguyen QT; Dény P; Ferrière F; Roulot D; Lortholary O; Jarrousse B; Danon F; Barrier JH; Ceccaldi J; Constans J; Crickx B; Fiessinger JN; Hachulla E; Jaccard A; Seligmann M; Kazatchkine M; Laroche L; Subra JF; Turlure P; Guillevin L
    Ann Med Interne (Paris); 1996; 147(2):81-6. PubMed ID: 8760684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
    Landau DA; Saadoun D; Halfon P; Martinot-Peignoux M; Marcellin P; Fois E; Cacoub P
    Arthritis Rheum; 2008 Feb; 58(2):604-11. PubMed ID: 18240235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon.
    Mauro E; Pedata M; Ermacora A; Mazzaro C
    Blood Transfus; 2012 Jan; 10(1):101-3. PubMed ID: 21839019
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.
    Colantuono S; Mitrevski M; Yang B; Tola J; Carlesimo M; De Sanctis GM; Fiorilli M; Casato M; Visentini M
    Clin Rheumatol; 2017 Mar; 36(3):617-623. PubMed ID: 28111716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
    Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM
    Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.